CN100439339C - 用作嗜中性白细胞弹性蛋白酶抑制剂的2-吡啶酮衍生物及其用途 - Google Patents

用作嗜中性白细胞弹性蛋白酶抑制剂的2-吡啶酮衍生物及其用途 Download PDF

Info

Publication number
CN100439339C
CN100439339C CNB2004800275174A CN200480027517A CN100439339C CN 100439339 C CN100439339 C CN 100439339C CN B2004800275174 A CNB2004800275174 A CN B2004800275174A CN 200480027517 A CN200480027517 A CN 200480027517A CN 100439339 C CN100439339 C CN 100439339C
Authority
CN
China
Prior art keywords
methyl
phenyl
oxo
trifluoromethyl
dihydropyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800275174A
Other languages
English (en)
Chinese (zh)
Other versions
CN1856467A (zh
Inventor
彼得·汉森
卡罗里娜·劳威兹
汉斯·洛恩
安东尼奥斯·尼基蒂迪斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29212489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100439339(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1856467A publication Critical patent/CN1856467A/zh
Application granted granted Critical
Publication of CN100439339C publication Critical patent/CN100439339C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
CNB2004800275174A 2003-09-18 2004-09-15 用作嗜中性白细胞弹性蛋白酶抑制剂的2-吡啶酮衍生物及其用途 Expired - Fee Related CN100439339C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302487A SE0302487D0 (sv) 2003-09-18 2003-09-18 Novel compounds
SE03024874 2003-09-18

Publications (2)

Publication Number Publication Date
CN1856467A CN1856467A (zh) 2006-11-01
CN100439339C true CN100439339C (zh) 2008-12-03

Family

ID=29212489

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800275174A Expired - Fee Related CN100439339C (zh) 2003-09-18 2004-09-15 用作嗜中性白细胞弹性蛋白酶抑制剂的2-吡啶酮衍生物及其用途

Country Status (25)

Country Link
US (1) US20070043036A1 (enExample)
EP (1) EP1663974B1 (enExample)
JP (1) JP2007505902A (enExample)
KR (1) KR20060096995A (enExample)
CN (1) CN100439339C (enExample)
AR (1) AR046083A1 (enExample)
AT (1) ATE420861T1 (enExample)
AU (1) AU2004272485B2 (enExample)
BR (1) BRPI0414570A (enExample)
CA (1) CA2538410A1 (enExample)
CO (1) CO5670357A2 (enExample)
DE (1) DE602004019110D1 (enExample)
ES (1) ES2319300T3 (enExample)
IL (1) IL173986A0 (enExample)
IS (1) IS8394A (enExample)
MX (1) MXPA06002723A (enExample)
NO (1) NO20061700L (enExample)
RU (1) RU2348617C2 (enExample)
SA (1) SA04250300B1 (enExample)
SE (1) SE0302487D0 (enExample)
TW (1) TW200526579A (enExample)
UA (1) UA84878C2 (enExample)
UY (1) UY28513A1 (enExample)
WO (1) WO2005026124A1 (enExample)
ZA (1) ZA200602262B (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JP2008544743A (ja) 2005-05-10 2008-12-11 インターミューン インコーポレイテッド ストレス活性化蛋白質キナーゼ系をモジュレートするためのピリドン誘導体
EP2281813A1 (en) 2005-08-08 2011-02-09 Pulmagen Therapeutics (Synergy) Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
CA2623957A1 (en) * 2005-09-29 2007-04-05 University Of Alberta Compositions for and methods of granzyme b inhibition
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
TW200808763A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
EP2077262A4 (en) 2006-10-23 2011-12-28 Takeda Pharmaceutical IMINOPYRIDINE DERIVATIVE AND USE THEREOF
ES2424851T3 (es) 2006-11-08 2013-10-09 Bristol-Myers Squibb Company Compuestos de piridona
EP2217591A4 (en) * 2007-11-06 2011-10-26 Astrazeneca Ab CERTAIN 2-PYRAZINONE DERIVATIVES AND THEIR USE AS NEUTROPHILES ELASTASE INHIBITORS
NZ585888A (en) 2007-12-14 2012-02-24 Pulmagen Therapeutics Asthma Ltd Indoles and their therapeutic use
PT2235002E (pt) 2008-01-23 2013-01-30 Bristol Myers Squibb Co Compostos de 4-piridinona e a sua utilização para o tratamento do cancro
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
WO2010094956A1 (en) 2009-02-17 2010-08-26 Pulmagen Therapeutics (Inflammation) Limited. Triazolopyridine derivatives as p38 map kinase inhibitors
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CA2773618A1 (en) * 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
EP2509952A1 (en) * 2009-12-08 2012-10-17 Boehringer Ingelheim International GmbH Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
US9040516B2 (en) 2011-08-01 2015-05-26 Sumitomo Dainippon Pharma Co., Ltd. Uracil derivative and use thereof for medical purposes
MY167216A (en) 2011-12-09 2018-08-14 Chiesi Farm Spa Kinase inhibitors
MY170656A (en) 2011-12-09 2019-08-24 Chiesi Farm Spa Kinase inhibitors
US9458154B2 (en) 2011-12-09 2016-10-04 Chiesi Farmaceutici S.P.A. Kinase inhibitors
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
HK1220459A1 (zh) 2013-06-06 2017-05-05 奇斯药制品公司 激酶抑制剂
US9221807B2 (en) 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
WO2017037116A1 (en) 2015-09-02 2017-03-09 Glaxosmithkline Intellectual Property (No.2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
AR107165A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
EP3394058B1 (en) 2015-12-23 2020-10-14 Chiesi Farmaceutici S.p.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
AR107164A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa INHIBIDORES DE QUINASA p38
WO2017191098A1 (en) 2016-05-05 2017-11-09 F. Hoffmann-La Roche Ag Pyrazole derivatives, compositions and therapeutic use thereof
BR112019004486A2 (pt) 2016-09-06 2019-05-28 Hoffmann La Roche compostos de 8-(azetidin-1-il)-[1,2,4] triazolo [1,5a] piridinil, composições e métodos de uso dos mesmos
PE20191236A1 (es) 2016-12-29 2019-09-11 Hoffmann La Roche Compuestos de pirazolopirimidina y metodos de uso de los mismos
WO2018166993A2 (en) 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof
JP7228318B6 (ja) 2017-05-22 2023-03-10 エフ． ホフマン－ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
SG11201909735YA (en) 2017-05-22 2019-11-28 Hoffmann La Roche Therapeutic compounds and compositions, and methods of use thereof
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2019139714A1 (en) 2018-01-15 2019-07-18 Genentech, Inc. Pyrazolopyrimidine compounds as jak inhibitors
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
CN110192948B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿腹部热敷贴
CN110192947B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿肺部热敷贴
EP3986899A1 (en) 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
CN114008051B (zh) 2019-06-18 2024-08-13 豪夫迈·罗氏有限公司 Jak激酶的吡唑并嘧啶砜抑制剂及其用途
WO2020257142A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
US20220354833A1 (en) 2019-09-17 2022-11-10 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
ES2962498T3 (es) 2020-04-16 2024-03-19 Mereo Biopharma 4 Ltd Métodos que implican el inhibidor de elastasa de neutrófilos alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina
US20240382472A1 (en) 2021-10-20 2024-11-21 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis
CN114057630B (zh) * 2021-12-23 2023-06-02 郑州大学 吡非尼酮衍生物及其合成方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
WO2002053543A1 (en) * 2000-12-28 2002-07-11 Shionogi & Co., Ltd. Pyridone derivative having affinity for cannabinoid 2-type receptor
GB2383326A (en) * 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
FR2687674B1 (fr) * 1992-02-07 1995-05-19 Roussel Uclaf Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
AU689158B2 (en) * 1993-11-19 1998-03-26 Parke, Davis & Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
RU2067579C1 (ru) * 1994-10-07 1996-10-10 Пермский фармацевтический институт 3-(2'-нафтоилметилен)-пиперазинон-2 и 1-n-фенил-3-фенацилиденпиперазинон-2, проявляющие противовоспалительную активность
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US7199136B2 (en) * 2001-12-20 2007-04-03 Bayer Healthcare Ag 1,4-dihydro-1,4-diphenylpyridine derivatives
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
WO2002053543A1 (en) * 2000-12-28 2002-07-11 Shionogi & Co., Ltd. Pyridone derivative having affinity for cannabinoid 2-type receptor
GB2383326A (en) * 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines

Also Published As

Publication number Publication date
CA2538410A1 (en) 2005-03-24
CO5670357A2 (es) 2006-08-31
KR20060096995A (ko) 2006-09-13
DE602004019110D1 (de) 2009-03-05
US20070043036A1 (en) 2007-02-22
JP2007505902A (ja) 2007-03-15
RU2348617C2 (ru) 2009-03-10
UA84878C2 (ru) 2008-12-10
TW200526579A (en) 2005-08-16
ES2319300T3 (es) 2009-05-06
ATE420861T1 (de) 2009-01-15
UY28513A1 (es) 2005-04-29
AU2004272485B2 (en) 2008-03-13
EP1663974B1 (en) 2009-01-14
BRPI0414570A (pt) 2006-11-07
SA04250300B1 (ar) 2008-09-07
AR046083A1 (es) 2005-11-23
ZA200602262B (en) 2007-07-25
SE0302487D0 (sv) 2003-09-18
NO20061700L (no) 2006-04-18
CN1856467A (zh) 2006-11-01
IL173986A0 (en) 2006-07-05
WO2005026124A1 (en) 2005-03-24
AU2004272485A1 (en) 2005-03-24
IS8394A (is) 2006-03-31
RU2006112427A (ru) 2007-11-10
EP1663974A1 (en) 2006-06-07
MXPA06002723A (es) 2006-06-06
HK1089167A1 (en) 2006-11-24

Similar Documents

Publication Publication Date Title
CN100439339C (zh) 用作嗜中性白细胞弹性蛋白酶抑制剂的2-吡啶酮衍生物及其用途
CN1882542B (zh) 用作嗜中性白细胞弹性蛋白酶抑制剂的2-吡啶酮衍生物及其用途
CN100427469C (zh) 作为嗜中性白细胞弹性蛋白酶抑制剂的喹啉衍生物及它们的用途
EP1562902B1 (en) 2-pyridone derivatives as inhibitors of neutrophile elastase
CN100424080C (zh) 作为嗜中性白细胞弹性蛋白酶抑制剂的喹喔啉衍生物及它们的用途
CN101142189A (zh) 作为嗜中性白细胞弹性蛋白酶的2-吡啶衍生物
HK1089167B (en) 2-pyridone derivatives as netrophil elastase inhibitors and their use
HK1089166B (en) 2-pyridone derivatives as neutrophil elastase inhibitors and their use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081203

Termination date: 20091015